

# Notice of Allowability

Application No.

10/507,272

Examiner

Marsha M. Tsay

Applicant(s)

MAGLIONE ET AL.

Art Unit

1656

## -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to after final amendment received November 1, 2007.
2. ☒ The allowed claim(s) is/are 16-18, 20-25 and 27-29.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
  5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
    - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
      - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
    - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

### Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material

5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_



KAREN COCHRANE CARLSON, PH.D  
PRIMARY EXAMINER

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Joseph Fischer on November 23, 2007.

The application has been amended as follows:

In the claims:

19. canceled

21. (currently amended) The method according to claim 16, wherein the medicament is in a form suitable for endovenous, intramuscular, ~~intra-articular~~ intra-articular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

22. (currently amended) The method according to claim ~~19~~ 24, wherein the medicament is in a form suitable for endovenous, intramuscular, ~~intra-articular~~ intra-articular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

24. (currently amended) A method of ~~cosmetic~~ treatment of a state comprising administering to adult individuals type 1 Placental Growth Factor (PLGF-1) to promote ~~perifollicular~~ perifollicular angiogenesis, wherein the state is ~~natural~~ loss of hair.

26. canceled

Art Unit: 1656

28. (currently amended) The method according to claim 23, wherein PLGF-1 is comprised in an amount suitable for an administration of ~~10 µg/Kg/day to 200 µg/Kg/day~~ 1 to 500 µg per Kg of body per day.

29. (currently amended) The method according to claim 24, wherein PLGF-1 is comprised in an amount suitable for an administration of ~~10 µg/Kg/day to 200 µg/Kg/day~~ 1 to 500 µg per Kg of body per day.

The following is an examiner's statement of reasons for allowance: claims 16-18, 20-25, 27-29 are drawn to a method of treating a state (i.e. scleroderma, skin aging, hair loss) comprising preparing a medicament comprising type 1 Placental Growth Factor (PLGF-1) and administering said medicament to a patient. Skin aging due to exposures to atmospheric agents or to protracted solar irradiation can include dry air or prolonged sun exposure. A search of the novel art reveals that there is no teaching that suggests a method of using PLGF-1 to treat the conditions of scleroderma, skin aging, and/or hair loss; therefore, the claims are deemed to be novel and unobvious.

Claims 16-18, 20-25, 27-29 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."


Art Unit: 1656

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marsha M. Tsay whose telephone number is 571-272-2938. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

November 23, 2007

  
KAREN COCHRANE CARLSON, PH.D  
PRIMARY EXAMINER